Anticholinergic treatment in airways diseases.

Hdl Handle:
http://hdl.handle.net/10147/139350
Title:
Anticholinergic treatment in airways diseases.
Authors:
Flynn, Robert A; Glynn, Deirdre A; Kennedy, Marcus P
Affiliation:
Sligo General Hospital, The Mall, Co., Republic of Ireland.
Citation:
Anticholinergic treatment in airways diseases. 2009, 26 (10):908-19 Adv Ther
Journal:
Advances in therapy
Issue Date:
Oct-2009
URI:
http://hdl.handle.net/10147/139350
DOI:
10.1007/s12325-009-0074-x
PubMed ID:
19967500
Additional Links:
http://www.ncbi.nlm.nih.gov/pubmed?term=19967500
Abstract:
The prevalence of chronic airways diseases such as chronic obstructive pulmonary disease and asthma is increasing. They lead to symptoms such as a cough and shortness of breath, partially through bronchoconstriction. Inhaled anticholinergics are one of a number of treatments designed to treat bronchoconstriction in airways disease. Both short-acting and long-acting agents are now available and this review highlights their efficacy and adverse event profile in chronic airways diseases.
Item Type:
Article
Language:
en
Description:
The prevalence of chronic airways diseases such as chronic obstructive pulmonary disease and asthma is increasing. They lead to symptoms such as a cough and shortness of breath, partially through bronchoconstriction. Inhaled anticholinergics are one of a number of treatments designed to treat bronchoconstriction in airways disease. Both short-acting and long-acting agents are now available and this review highlights their efficacy and adverse event profile in chronic airways diseases.
MeSH:
Asthma; Cholinergic Antagonists; Chronic Disease; Cost-Benefit Analysis; Humans; Ipratropium; Pulmonary Disease, Chronic Obstructive; Randomized Controlled Trials as Topic; Scopolamine Derivatives
ISSN:
1865-8652

Full metadata record

DC FieldValue Language
dc.contributor.authorFlynn, Robert Aen
dc.contributor.authorGlynn, Deirdre Aen
dc.contributor.authorKennedy, Marcus Pen
dc.date.accessioned2011-08-10T15:32:56Z-
dc.date.available2011-08-10T15:32:56Z-
dc.date.issued2009-10-
dc.identifier.citationAnticholinergic treatment in airways diseases. 2009, 26 (10):908-19 Adv Theren
dc.identifier.issn1865-8652-
dc.identifier.pmid19967500-
dc.identifier.doi10.1007/s12325-009-0074-x-
dc.identifier.urihttp://hdl.handle.net/10147/139350-
dc.descriptionThe prevalence of chronic airways diseases such as chronic obstructive pulmonary disease and asthma is increasing. They lead to symptoms such as a cough and shortness of breath, partially through bronchoconstriction. Inhaled anticholinergics are one of a number of treatments designed to treat bronchoconstriction in airways disease. Both short-acting and long-acting agents are now available and this review highlights their efficacy and adverse event profile in chronic airways diseases.en
dc.description.abstractThe prevalence of chronic airways diseases such as chronic obstructive pulmonary disease and asthma is increasing. They lead to symptoms such as a cough and shortness of breath, partially through bronchoconstriction. Inhaled anticholinergics are one of a number of treatments designed to treat bronchoconstriction in airways disease. Both short-acting and long-acting agents are now available and this review highlights their efficacy and adverse event profile in chronic airways diseases.-
dc.language.isoenen
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pubmed?term=19967500en
dc.subject.meshAsthma-
dc.subject.meshCholinergic Antagonists-
dc.subject.meshChronic Disease-
dc.subject.meshCost-Benefit Analysis-
dc.subject.meshHumans-
dc.subject.meshIpratropium-
dc.subject.meshPulmonary Disease, Chronic Obstructive-
dc.subject.meshRandomized Controlled Trials as Topic-
dc.subject.meshScopolamine Derivatives-
dc.titleAnticholinergic treatment in airways diseases.en
dc.typeArticleen
dc.contributor.departmentSligo General Hospital, The Mall, Co., Republic of Ireland.en
dc.identifier.journalAdvances in therapyen
dc.description.provinceConnacht-

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.